A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density

Statistical Methods in Medical Research

Volumn 25, Issue 1, 2016, Pages 400-412

  Detilleux, J ^a   Reginster, J Y ^a   Chines, A ^b   Bruyere O ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b PFIZER INC   (United States)

Author keywords

bazedoxifene acetate; bone mineral density; Causal analysis; piecewise regression; structural equation model; vertebral fracture

Indexed keywords

BAZEDOXIFENE; PLACEBO; BONE DENSITY CONSERVATION AGENT; INDOLE DERIVATIVE;

AGE; ARTICLE; BAYES THEOREM; BAYESIAN PATH ANALYSIS; BODY MASS; BONE DENSITY; FEMUR NECK; FORECASTING; HIP; HUMAN; MEASUREMENT ACCURACY; OSTEOPOROSIS; PIECEWISE REGRESSION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; SPINE FRACTURE; STRUCTURAL EQUATION MODELING; BIOSTATISTICS; DRUG EFFECTS; FEMALE; NONLINEAR SYSTEM; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BAYES THEOREM; BIOSTATISTICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; INDOLES; MODELS, STATISTICAL; NONLINEAR DYNAMICS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 84958721286     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280212456655     Document Type: Article

References (40)

1. Johnell O, Kanis JA,. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-1733.
2. Ho-Pham LT, Nguyen ND, Vu BQ, et al. Prevalence and risk factors of radiographic vertebral fracture in postmenopausal Vietnamese women. Bone 2009; 45: 213-217.
3. van der Klift M, de Laet CD, Pols HA,. Assessment of fracture risk: who should be treated for osteoporosis? Best Pract Res Clin Rheumatol 2005; 19: 937-950.
4. Ross PD,. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996; 156: 1399-1411.
5. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 3076-3081.
6. Hartl F, Tyndall A, Kraenzlin M, et al. Discriminatory ability of quantitative ultrasound parameters and bone mineral density in a population-based sample of postmenopausal women with vertebral fractures: results of the Basel Osteoporosis Study. J Bone Miner Res 2002; 17: 321-330.
7. Weinans H,. Architectural changes independent of bone mineral in osteoporosis. J Musculoskelet Neuronal Interact 2002; 2: 535-537.
8. Wegrzyn J, Roux JP, Arlot ME, et al. Role of trabecular microarchitecture and its heterogeneity parameters in the mechanical behavior of ex vivo human L3 vertebrae. J Bone Miner Res 2010; 25: 2324-2331.
9. FRAX®-Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/. Accessed on February10, 2012.
10. Small RE,. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 2005; 7: 3-3.
11. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23: 525-535.
12. Freedman LS, Graubard BI, Schatzkin A,. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-178.
13. Li Z, Meredith MP, Hoseyni MS,. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001; 20: 3175-3188.
14. Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
15. Hafeman DM,. "Proportion explained": a causal interpretation for standard measures of indirect effect? Am J Epidemiol 2009; 170: 1443-1448.
16. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93: 861-868.
17. Itabashi A, Yoh K, Chines AA, et al. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 2011; 26: 519-529.
18. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-289.
19. Kupek E,. Beyond logistic regression: structural equations modelling for binary variables and its application to investigating unobserved confounders. BMC Med Res Methodol 2006; 6: 13-13.
20. Ditlevsen S, Christensen U, Lynch J, et al. The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 2005; 16: 114-120.
21. Qu Y, Case M,. Quantifying the indirect treatment effect via surrogate markers. Stat Med 2006; 25: 223-231.
22. Have TR, Joffe MM, Lynch KG, et al. Causal mediation analyses with rank preserving models. Biometrics 2007; 63: 926-934.
23. Imai K, Keele L, Yamamoto T,. Identification, inference and sensitivity analysis for causal mediation effects. Stat Sci 2010; 25: 51-71.
24. VanderWeele TJ, Vansteelandt S,. Conceptual issues concerning mediation, interventions and composition. Stat Interface 2009; 2: 457-468.
25. Petersen ML, Sinisi SE, van der Laan MJ,. Estimation of direct causal effects. Epidemiology 2006; 17: 276-284.
26. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923-1934.
27. Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-724.
28. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20: 275-282.
29. Jacobs JW, Da Silva JA, Armbrecht G, et al,. Prediction of vertebral fractures is specific for gender and site of bone mineral density measurement. J Rheumatol 2010; 37: 149-154.
30. Lunn DJ, Thomas A, Best N, et al. WinBUGS a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-337.
31. Ahlborg HG, Johnell O, Turner CH, et al. Bone loss and bone size after menopause. N Engl J Med 2003; 349: 327-334.
32. Barrera G, Bunout D, Gattas V, et al. A high body mass index protects against femoral neck osteoporosis in healthy elderly subjects. Nutrition 2004; 20: 769-771.
33. Pirro M, Fabbriciani G, Leli C, et al. High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women. J Bone Miner Metab 2010; 28: 88-93.
34. Ferrar L, Roux C, Felsenberg D, et al. Association between incident and baseline vertebral fractures in European women: vertebral fracture assessment in the Osteoporosis and Ultrasound Study (OPUS). Osteoporos Int 2012; 23: 59-65.
35. Roux C, Fechtenbaum J, Kolta S, et al. Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 2007; 18: 1617-1624.
36. Berger C, Goltzman D, Langsetmo L, et al. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010; 25: 1948-1957.
37. Langsetmo L, Hanley DA, Prior JC, et al. Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged >/= 50 y: a population-based cohort study. Am J Clin Nutr 2011; 93: 192-199.
38. Li W-F, Hou S-X, Yu B, et al. Genetics of osteoporosis: perspectives for personalized medicine. Personal Med 2010; 7: 655-668.
39. Marini F, Brandi ML,. Pharmacogenetics of osteoporosis. F1000 Biol Rep. 2010; 2: 63-63.
40. Ten have TR, Joffe MM,. A review of causal estimation of effects in mediation analyses. Stat Meth Med Res 2012; 21: 77-107.